Scotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $44.00

Keros Therapeutics (NASDAQ:KROS) had its price objective lowered by investment analysts at Scotiabank from $77.00 to $44.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has a “sector outperform” rating on the stock. Scotiabank’s target price would suggest a potential upside of 133.67% from the company’s previous close.

Several other analysts have also recently commented on KROS. Jefferies Financial Group started coverage on Keros Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating on the stock. William Blair lowered shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Thursday. Guggenheim reissued a “buy” rating and set a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a research note on Wednesday, December 4th. BTIG Research lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday. Finally, Bank of America decreased their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $85.67.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $18.83 on Friday. The firm has a market cap of $762.75 million, a PE ratio of -3.61 and a beta of 1.20. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00. The firm’s fifty day moving average is $59.11 and its 200-day moving average is $52.65.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same quarter in the previous year, the firm earned ($1.33) earnings per share. The company’s revenue for the quarter was up 4750.0% on a year-over-year basis. Sell-side analysts forecast that Keros Therapeutics will post -5.26 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. KBC Group NV increased its position in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics in the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Keros Therapeutics during the second quarter valued at approximately $128,000. Finally, LMR Partners LLP acquired a new position in shares of Keros Therapeutics during the third quarter worth approximately $213,000. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.